

Benjamin Peter Geisler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7996929/publications.pdf>

Version: 2024-02-01

72
papers

1,114
citations

623734

14
h-index

454955

30
g-index

84
all docs

84
docs citations

84
times ranked

1776
citing authors

#	ARTICLE	IF	CITATIONS
1	Case management in a COVID-19 surge: A single-institution study of disposition and access to post-acute care. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 372-375.	2.6	1
2	Cost-Effectiveness of Urea Excipient-Based Drug-Coated Balloons for Chronic Limb-Threatening Ischemia from Femoropopliteal Disease in the Netherlands and Germany. <i>CardioVascular and Interventional Radiology</i> , 2022, 45, 298-305.	2.0	3
3	An assessment of annual procedure volumes and therapy adoption of transcatheter closure of patent foramen ovale in four European countries. <i>European Stroke Journal</i> , 2021, 6, 72-80.	5.5	7
4	Blood pressure control in Australian general practice: analysis using general practice records of 1.2 million patients from the MedicinesInsight database. <i>Journal of Hypertension</i> , 2021, 39, 1134-1142.	0.5	9
5	Racial/ethnic and socioeconomic variations in hospital length of stay. <i>Medicine (United States)</i> , 2021, 100, e25976.	1.0	28
6	Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review. <i>Systematic Reviews</i> , 2021, 10, 143.	5.3	2
7	Letter to the editor regarding Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis. <i>Critical Care</i> , 2021, 25, 285.	5.8	3
8	Principles of Economic Evaluation in a Pandemic Setting: An Expert Panel Discussion on Value Assessment During the Coronavirus Disease 2019 Pandemic. <i>Pharmacoeconomics</i> , 2021, 39, 1201-1208.	3.3	8
9	A Diagnostic Model for Kawasaki Disease Based on Immune Cell Characterization From Blood Samples. <i>Frontiers in Pediatrics</i> , 2021, 9, 769937.	1.9	1
10	Hydroxychloroquine Toxicity. <i>Journal of Clinical Rheumatology</i> , 2020, Publish Ahead of Print, .	0.9	1
11	Adoption Patterns of Bronchoscopic Lung Volume Reduction Procedures in Germany and Predicted Procedure Volumes for Other European Countries. <i>Respiration</i> , 2019, 97, 34-41.	2.6	3
12	Utilizing a PLASMIC score-based approach in the management of suspected immune thrombotic thrombocytopenic purpura: a cost minimization analysis within the Harvard TMA Research Collaborative. <i>British Journal of Haematology</i> , 2019, 186, 490-498.	2.5	20
13	Clinical and Economic Benefits of Upper Airway Stimulation for Obstructive Sleep Apnea in a European Setting. <i>Respiration</i> , 2019, 98, 38-47.	2.6	13
14	Model to evaluate the impact of hospital-based interventions targeting false-positive blood cultures on economic and clinical outcomes. <i>Journal of Hospital Infection</i> , 2019, 102, 438-444.	2.9	14
15	Study Comparing Traditional Versus Alternative Metrics to Measure the Impact of the Critical Care Medicine Literature. , 2019, 1, e0028.		4
16	PIN44 A MODEL TO EVALUATE THE IMPACT OF HOSPITAL-BASED INTERVENTIONS TARGETING FALSE-POSITIVE BLOOD CULTURES ON ECONOMIC AND CLINICAL OUTCOMES. <i>Value in Health</i> , 2019, 22, S201.	0.3	0
17	Meniscus Root Repair vs Meniscectomy or Nonoperative Management to Prevent Knee Osteoarthritis After Medial Meniscus Root Tears: Clinical and Economic Effectiveness. <i>American Journal of Sports Medicine</i> , 2019, 47, 762-769.	4.2	156
18	Cost-effectiveness of transcatheter versus surgical aortic valve replacement in patients at lower surgical risk: results from the NOTION trial. <i>EuroIntervention</i> , 2019, 15, e959-e967.	3.2	23

#	ARTICLE	IF	CITATIONS
19	Cost-effectiveness of programmed cell death protein 1/programmed death-ligand 1 inhibitors (aPD1/aPDL1) varies widely.. Journal of Clinical Oncology, 2019, 37, e18351-e18351.	1.6	0
20	Racial and Geographic Disparities in Interhospital ICU Transfers*. Critical Care Medicine, 2018, 46, e76-e80.	0.9	27
21	Cost-effectiveness of orbital atherectomy compared to rotational atherectomy in treating patients with severely calcified coronary artery lesions in Japan. Cardiovascular Intervention and Therapeutics, 2018, 33, 328-336.	2.3	6
22	Outcomes of Ventilated Patients With Sepsis Who Undergo Interhospital Transfer: A Nationwide Linked Analysis*. Critical Care Medicine, 2018, 46, e81-e86.	0.9	20
23	PMD54 - DRUG-COATED BALLOON THERAPY FOR TREATMENT OF CRITICAL LIMB ISCHEMIA IN FEMOROPOPLITEAL ARTERY DISEASE: ECONOMIC ANALYSIS FOR THE NETHERLANDS. Value in Health, 2018, 21, S252.	0.3	0
24	Economic Analysis of Urea-Excipient Drug-Coated Balloon Therapy for Treatment of Femoropopliteal Artery Disease in Japan. Value in Health, 2018, 21, S7.	0.3	0
25	Budget Impact of Orbital Atherectomy Compared to Rotational Atherectomy in Patients with Severely Calcified Coronary Artery Lesions in Japan. Value in Health, 2018, 21, S69.	0.3	0
26	Trends in Utilization of Endovascular Arterial Revascularization Modalities Below the Knee in Germany 2009-16. Value in Health, 2018, 21, S177.	0.3	1
27	Should Surgical Repair Be Recommended Over Nonoperative Management for Medial Meniscus Root Tears? Response. American Journal of Sports Medicine, 2018, 46, NP44-NP45.	4.2	4
28	Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 1223-1232.	1.1	8
29	Value in Oral and Maxillofacial Surgery: A Systematic Review of Economic Analyses. Journal of Oral and Maxillofacial Surgery, 2017, 75, 2287-2303.	1.2	12
30	Response to Lee etÂal.. Journal of Thoracic Oncology, 2017, 12, e152-e153.	1.1	0
31	Clinical And Economic Benefit Of Upper Airway Stimulation For Obstructive Sleep Apnea In The German Setting. Value in Health, 2017, 20, A581.	0.3	0
32	Cost-Effectiveness and Projected Survival of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement for High Risk Patients in a European Setting: A Dutch Analysis Based on the CoreValve High Risk Trial. Structural Heart, 2017, 1, 267-274.	0.6	9
33	Economic analysis of endovascular drug-eluting treatments for femoropopliteal artery disease in the UK. BMJ Open, 2016, 6, e011245.	1.9	60
34	Economic Analysis of Endovascular Interventions for The Treatment of Femoropopliteal Peripheral Artery Disease in Austria. Value in Health, 2016, 19, A690.	0.3	0
35	Economic Analysis of Drug-Coated Balloons And Other Endovascular Treatments For Femoropopliteal Artery Disease In The United Kingdom. Value in Health, 2016, 19, A5.	0.3	0
36	COST EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION VERSUS SURGICAL AORTIC VALVE REPLACEMENT: THE COREVALVE HIGH RISK TRIAL FROM A DUTCH PERSPECTIVE. Value in Health, 2016, 19, A305.	0.3	0

#	ARTICLE	IF	CITATIONS
37	Cardiovascular Benefits of the Mediterranean Diet Are Driven by Stroke Reduction and Possibly by Decreased Atrial Fibrillation Incidence. <i>American Journal of Medicine</i> , 2016, 129, e11.	1.5	5
38	Dyspnea and Chest Pain in a Young Woman Caused by a Giant Pericardial Lymphohemangioma: Diagnosis and Treatment. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1260.e23-1260.e25.	1.7	4
39	Utilization and Cost Effectiveness of a Risk Stratified Diagnostic Approach to Patients with Suspected Thrombotic Thrombocytopenic Purpura. <i>Blood</i> , 2016, 128, 1456-1456.	1.4	2
40	Adoption Of Transcatheter Aortic Valve Replacement In Germany: Utilization Patterns And Case Volumes Compared To Surgical Aortic Valve Replacement In The Period 2009-2013. <i>Value in Health</i> , 2015, 18, A370.	0.3	0
41	Cost-Effectiveness of Transcatheter Aortic Valve Replacement: Current Decision-Analytic Models and Future Opportunities. <i>Value in Health</i> , 2015, 18, A359.	0.3	1
42	Cost-effectiveness and cost-utility of a structured collaborative disease management in the Interdisciplinary Network for Heart Failure (INH) study. <i>Clinical Research in Cardiology</i> , 2015, 104, 304-309.	3.3	13
43	Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome. , 2015, 3, 4.		122
44	Endovascular Interventions For Treatment Of Femoropopliteal Peripheral Artery Disease: Updated Budget Impact Analysis For Germany Based On Latest Clinical Evidence. <i>Value in Health</i> , 2015, 18, A349.	0.3	1
45	Gabapentin Treatment for Alcohol Dependence. <i>JAMA Internal Medicine</i> , 2014, 174, 1201.	5.1	3
46	Economic analysis of endovascular interventions for femoropopliteal arterial disease: A systematic review and budget impact model for the United States and Germany. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 546-554.	1.7	51
47	Estimated Added Benefit Of Catheter-Based Renal Denervation For Moderate Treatment-Resistant Hypertension: Impact Of Age And Cardiovascular Risk Factors. <i>Value in Health</i> , 2014, 17, A474.	0.3	0
48	Health-Economic Assessment of the Use of Catheter-Based Renal Denervation in Patients with Resistant Hypertension in Mexico. <i>Value in Health</i> , 2013, 16, A705.	0.3	1
49	Cost-effectiveness of catheter-based renal denervation for resistant hypertension â€“ a canadian perspective. <i>Value in Health</i> , 2013, 16, A284-A285.	0.3	1
50	Gender differences in added benefit of catheter-based renal denervation for resistant hypertension: model-based estimation of unadjusted and quality-adjusted life year gains in males and females. <i>European Heart Journal</i> , 2013, 34, P4491-P4491.	2.2	0
51	Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1271-1277.	2.8	126
52	PMD57 New Approaches for Graphing Probabilistic Patient-Relevant Health Outcomes: The Case of Renal Denervation for Resistant Hypertension. <i>Value in Health</i> , 2012, 15, A72.	0.3	0
53	PMD20 Budget Impact of Drug Eluting Balloons for Intermittent Claudication From Superficial Femoral Artery Disease in the United States Health Care System. <i>Value in Health</i> , 2012, 15, A348.	0.3	0
54	PMD23 Long-Term Clinical Effectiveness and Cost-Effectiveness of Catheter-Based Renal Denervation in the UK. A Model-Based Projection Based on the Symplicity HTN-2 Trial. <i>Value in Health</i> , 2012, 15, A349.	0.3	1

#	ARTICLE	IF	CITATIONS
55	Trauma and Burn Education: A Global Survey. World Journal of Surgery, 2012, 36, 548-555.	1.6	8
56	Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure. Pharmacoeconomics, 2011, 29, 753-769.	3.3	31
57	Perspectives on "Early Dialogue" between a Manufacturer and Health Technology Assessment Agencies. Value in Health, 2011, 14, 607.	0.3	0
58	Use of Observation Care in US Emergency Departments, 2001 to 2008. PLoS ONE, 2011, 6, e24326.	2.5	112
59	Determining Health-Related Quality of Life and Health State Utility Values of Urinary Incontinence in Women. Female Pelvic Medicine and Reconstructive Surgery, 2011, 17, 305-307.	1.1	7
60	Health State Survey-Derived Utilities in Cost-Utility Analysis" A Call to Action. Value in Health, 2010, 13, 159.	0.3	1
61	Treating anemia in heart failure patients: a review of erythropoiesis-stimulating agents. Expert Opinion on Biological Therapy, 2010, 10, 1209-1216.	3.1	4
62	Leadership in health care. Journal of Health Organization and Management, 2010, 24, 258-276.	1.3	4
63	Estimates of Electronic Medical Records in U.S. Emergency Departments. PLoS ONE, 2010, 5, e9274.	2.5	29
64	Risk of bias in meta-analysis on erythropoietin-stimulating agents in heart failure. Heart, 2009, 95, 1278-1279.	2.9	7
65	Deterministic Sensitivity Analysis for First-Order Monte Carlo Simulations: A Technical Note. Value in Health, 2009, 12, 96-97.	0.3	4
66	Utility Estimates for Decision"Analytic Modeling in Chronic Heart Failure" Health States Based on New York Heart Association Classes and Number of Rehospitalizations. Value in Health, 2009, 12, 185-187.	0.3	98
67	PHP9 THE IMPACT OF LEGISLATION AND PRICING ON GENERIC DRUG UTILIZATION: AN ANALYSIS OF 26 COUNTRIES. Value in Health, 2009, 12, A80.	0.3	0
68	Additional Factors That Could Improve Cost-Effectiveness of Pharmacogenetic-Guided Dosing in Warfarin Therapy. Annals of Internal Medicine, 2009, 151, 71.	3.9	0
69	Decision"analytic evaluation of the clinical effectiveness and cost"effectiveness of management programmes in chronic heart failure. European Journal of Heart Failure, 2008, 10, 1026-1032.	7.1	26
70	Do Insurers Compete on the Federal Health Insurance Exchange?. F1000Research, 0, 4, 25.	1.6	0
71	Prior Statin Use Is Associated with Decreased Mortality and Lower Levels of Liver and Brain Organ Failure Scores in Sepsis - A Matched Observational Study. SSRN Electronic Journal, 0, , .	0.4	0
72	The Effect of Standardized Hospitalist Information Cards on the Patient Experience: a Quasi-Experimental Prospective Cohort Study. Journal of General Internal Medicine, 0, , .	2.6	2